CD14 and cancer: This in vitro model of the cancer TME generates CD14+HLA-DRlo/neg cells with decreased capacity to mature into dendritic cells, elaborate proangiogenic factors, and potently inhibit T-cell proliferation, similar to what is observed with cancer-patient-derived CD14+HLA-DRlo/neg cells [11,12,13].